JP2016521755A - 代謝障害を治療するための組成物および方法 - Google Patents

代謝障害を治療するための組成物および方法 Download PDF

Info

Publication number
JP2016521755A
JP2016521755A JP2016519696A JP2016519696A JP2016521755A JP 2016521755 A JP2016521755 A JP 2016521755A JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016521755 A JP2016521755 A JP 2016521755A
Authority
JP
Japan
Prior art keywords
major component
metabolic disorder
receptor agonist
sumn
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521755A5 (enExample
Inventor
エイチ． シンコッタ，アンソニー
エイチ． シンコッタ，アンソニー
チャン，ヤホン
Original Assignee
ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー filed Critical ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー
Publication of JP2016521755A publication Critical patent/JP2016521755A/ja
Publication of JP2016521755A5 publication Critical patent/JP2016521755A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2016519696A 2013-06-13 2014-06-13 代謝障害を治療するための組成物および方法 Pending JP2016521755A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834864P 2013-06-13 2013-06-13
US61/834,864 2013-06-13
PCT/US2014/042397 WO2014201411A1 (en) 2013-06-13 2014-06-13 Compositions and methods for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2016521755A true JP2016521755A (ja) 2016-07-25
JP2016521755A5 JP2016521755A5 (enExample) 2017-07-27

Family

ID=52022819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519696A Pending JP2016521755A (ja) 2013-06-13 2014-06-13 代謝障害を治療するための組成物および方法

Country Status (9)

Country Link
US (3) US20150011554A1 (enExample)
EP (2) EP3008167A4 (enExample)
JP (1) JP2016521755A (enExample)
CN (1) CN105579575A (enExample)
AU (1) AU2014277952A1 (enExample)
BR (1) BR112015031249A2 (enExample)
CA (1) CA2915405A1 (enExample)
MX (1) MX2015017253A (enExample)
WO (1) WO2014201411A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
CN120713906A (zh) 2016-04-20 2025-09-30 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
EP3697418B1 (en) 2017-10-18 2024-07-24 VeroScience LLC Improved bromocriptine formulations
WO2019113110A2 (en) * 2017-12-05 2019-06-13 Peter Vanderklish Modulation of ampa/kainate receptors for the treatment of hypoglycemia
US12343359B2 (en) 2019-05-23 2025-07-01 Dignity Health Inhibitory interneuron treatment methods, uses and compositions for diabetes
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049636A1 (en) * 2000-12-19 2002-06-27 Rajagopal Thiruvengadam An antidiabetic composition of amino acids
JP2004530680A (ja) * 2001-05-04 2004-10-07 イーライ・リリー・アンド・カンパニー ２型糖尿病治療薬製造のためのａｍｐａ受容体増強物質の使用
US20060183803A1 (en) * 2005-02-17 2006-08-17 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of assorted health problems

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784703A (en) * 1972-02-29 1974-01-08 Merck & Co Inc Method of treating hypertension
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
CZ282909B6 (cs) * 1991-12-23 1997-11-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
CA2450801C (en) 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US6274600B1 (en) 1995-06-05 2001-08-14 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors
US20020099050A1 (en) 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US5488049A (en) 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
US5852008A (en) 1995-01-24 1998-12-22 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5686423A (en) * 1996-02-16 1997-11-11 Department Of Health, The Executive Yuan, Republic Of China Di-and tri-peptide mimetic compounds for Parkinson's disease
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
WO1998012185A1 (en) 1996-09-17 1998-03-26 The Regents Of The University Of California Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
WO1998017306A1 (en) * 1996-10-22 1998-04-30 Ergo Research Corporation Method for increasing blood insulin levels in mammals
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6110935A (en) 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6174922B1 (en) 1998-05-11 2001-01-16 Eli Lilly And Company Sulphonamide derivatives
BR9908199A (pt) 1998-02-24 2001-04-03 Lilly Co Eli Derivados de sulfonamida
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
WO1999057119A1 (en) * 1998-05-04 1999-11-11 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
PE20000943A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
PE20000944A1 (es) 1998-07-31 2000-09-20 Lilly Co Eli Derivados de sulfonamida
JP2002521445A (ja) 1998-07-31 2002-07-16 イーライ・リリー・アンド・カンパニー 複素環スルホンアミド誘導体
DE69917278T2 (de) 1998-07-31 2005-05-19 Eli Lilly And Co., Indianapolis Heterocyclyl sulphonamid derivate
WO2000006537A1 (en) 1998-07-31 2000-02-10 Eli Lilly And Company N-substituted sulfonamide derivatives
AU5233999A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Alkenyl sulphonamide derivatives
US6552086B1 (en) 1998-07-31 2003-04-22 Eli Lilly And Company Sulfonamide derivatives
AU5235699A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Sulfonamide derivatives
US6521605B1 (en) 1998-07-31 2003-02-18 Eli Lilly And Company Amidophosphate derivatives
US6358981B1 (en) 1998-07-31 2002-03-19 Eli Lilly And Company Sulphonamide derivatives
HRP20010800A2 (en) 1999-04-30 2002-12-31 Lilly Co Eli Monofluoroalkyl derivatives
WO2000075123A1 (en) 1999-06-04 2000-12-14 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4h-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of ampa
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6639107B1 (en) 1999-12-08 2003-10-28 Eli Lilly And Company Cyclopentyl sulfonamide derivatives
DE60039631D1 (de) 1999-12-08 2008-09-04 Lilly Co Eli Cyclopentyl sulfonamid derivaten
DE10004572A1 (de) 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AU2001241512A1 (en) 2000-03-13 2001-09-24 Eli Lilly And Company Sulfonamide derivatives
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
EP1311474A1 (en) 2000-05-19 2003-05-21 Eli Lilly And Company Sulfonamide derivatives
HRP20020917A2 (en) 2000-05-19 2004-02-29 Lilly Co Eli Sulfonamide derivatives
AU2001262932A1 (en) 2000-06-06 2001-12-17 Eli Lilly And Company (bis)sulfonamide derivatives
ATE272617T1 (de) 2000-06-13 2004-08-15 Lilly Co Eli Sulfonamid-derivate
WO2002014294A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
AU2001280470A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
WO2002018329A1 (en) 2000-08-31 2002-03-07 Eli Lilly And Company Acetylenic sulfonamide derivatives
CA2421597A1 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Cycloalkylfluorosulfonamide derivatives
ITBO20010271A1 (it) 2001-05-08 2002-11-08 Giuseppe Cannazza Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl
US20030100552A1 (en) 2001-05-17 2003-05-29 Boehringer Ingelheim Pharma Kg Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions
US20040157817A1 (en) 2001-05-30 2004-08-12 Cantell Buddy Eugene Cycloalkenylsulfonamide derivatives
WO2002098846A1 (en) 2001-06-05 2002-12-12 Eli Lilly And Company Sulfonamide derivatives
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
WO2003011269A1 (de) * 2001-07-31 2003-02-13 Lothar Saiger Mittel zur behandlung der symptome von demenzerkrankungen enthalten ein zusatzliches lokalanasthetikum
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
CZ2004632A3 (cs) 2001-11-26 2004-08-18 Cortexápharmaceuticalsźáinc Karbonylbenzoxazinové sloučeniny pro zvýšení glutamátergních synaptických odpovědí
WO2004009665A2 (en) * 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
US9655865B2 (en) * 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) * 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20050054652A1 (en) * 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7625932B2 (en) 2003-10-08 2009-12-01 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
GB0407583D0 (en) * 2004-04-05 2004-05-05 Arbab Tarig S M Diagnostic testing and related matters
JPWO2005110394A1 (ja) * 2004-05-19 2008-03-21 味の素株式会社 糖尿病治療薬
EP1751087B1 (en) 2004-06-04 2012-06-27 XenoPort, Inc. Levodopa derivatives, and compositions and uses thereof
GB0417709D0 (en) 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
AU2005270377A1 (en) 2004-08-09 2006-02-16 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
US20070270471A1 (en) 2004-08-09 2007-11-22 Glaxo Group Limited Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine
US20060167099A1 (en) * 2004-11-09 2006-07-27 Anat Biegon Use of compositions that increase glutamate receptor activity in treatment of brain injury
WO2006087169A1 (en) 2005-02-15 2006-08-24 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
WO2006138243A2 (en) * 2005-06-13 2006-12-28 University Of Vermont And State Agricultural College Inhibition of creatine uptake to promote weight loss
PL2135603T3 (pl) * 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
EP1960373A2 (en) 2005-11-22 2008-08-27 NeuroSearch A/S Novel quinoxaline derivatives and their medical use
WO2007090840A1 (en) 2006-02-08 2007-08-16 Glaxo Group Limited 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia
GB0602560D0 (en) 2006-02-08 2006-03-22 Glaxo Group Ltd Compounds
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2125702A1 (en) 2006-12-21 2009-12-02 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
GB0721092D0 (en) * 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
GB0721094D0 (en) * 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
CN101990431B (zh) * 2008-03-12 2014-06-18 迈阿密大学 用于检测和治疗低血糖症的方法和测定法
WO2010015037A1 (en) * 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
GB0821166D0 (en) * 2008-11-19 2008-12-24 Glaxo Group Ltd Compounds
GB0822425D0 (en) * 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
WO2010121023A2 (en) * 2009-04-15 2010-10-21 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
US10206921B2 (en) 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US20120283193A1 (en) * 2009-10-31 2012-11-08 The Regents Of The University Of California Manipulation of brain in a circuit-specific manner
AR082618A1 (es) * 2010-08-10 2012-12-19 Takeda Pharmaceutical Derivados de tiadiazina, composiciones farmaceuticas y usos
US8697898B2 (en) 2011-11-23 2014-04-15 Instytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego PAN Medical application of lipid derivatives of dopamine and the methods of their production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049636A1 (en) * 2000-12-19 2002-06-27 Rajagopal Thiruvengadam An antidiabetic composition of amino acids
JP2004530680A (ja) * 2001-05-04 2004-10-07 イーライ・リリー・アンド・カンパニー ２型糖尿病治療薬製造のためのａｍｐａ受容体増強物質の使用
US20060183803A1 (en) * 2005-02-17 2006-08-17 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of assorted health problems

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ, vol. 106, no. 2, JPN6018012184, 1992, pages 354 - 359, ISSN: 0004085182 *
ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ, vol. 285, no. 29, JPN6018012177, 2010, pages 21913 - 21921, ISSN: 0004085180 *
ＮＥＷ薬理学（改訂代６版）, JPN6018012181, 5 April 2011 (2011-04-05), pages 88 - 96, ISSN: 0004085181 *

Also Published As

Publication number Publication date
EP3008167A1 (en) 2016-04-20
AU2014277952A1 (en) 2016-01-28
WO2014201411A1 (en) 2014-12-18
US20150011554A1 (en) 2015-01-08
CA2915405A1 (en) 2014-12-18
US20220142960A1 (en) 2022-05-12
EP3008167A4 (en) 2017-06-07
BR112015031249A2 (pt) 2017-07-25
CN105579575A (zh) 2016-05-11
EP3311842A1 (en) 2018-04-25
MX2015017253A (es) 2016-04-19
US20190160059A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US20220142960A1 (en) Compositions and Methods for Treating Metabolic Disorders
JP5980840B2 (ja) インスリン感受性を増すための組成物および方法
Villégier et al. Tranylcypromine enhancement of nicotine self-administration
KR20120028342A (ko) 약물 중독 치료 및 중독 관련 행동의 개선을 위한 조성물
CA2689012A1 (en) Method for the treatment of neurological and neuropsychological disorders
WO2011069051A1 (en) Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
BRPI0912607A2 (pt) medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete
US11648295B2 (en) Methods of treating diseases resulting from a maladapted stress response
AU2012258219A1 (en) Use of sigma ligands in diabetes type-2 associated pain
WO2011133212A1 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
AU2006242851A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
WO2012101292A1 (es) Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
JP2021505668A (ja) 併用療法（睡眠障害およびｃｎｓ障害）において使用するためのｎｍｄａ受容体モジュレーター（ラパスチネル）の組合せ
KR20200026962A (ko) 염증 반응을 포함하는 통증 상태에서 무통증을 위한 말초 제한된 이중 작용성 카파 및 델타 오피오이드 작용제
WO2012054817A1 (en) Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)
WO2014155184A1 (en) Treatment for parkinson's disease
HK1233527A1 (en) Composition and methods for increasing insulin sensitivity
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730